E-Power Inc. revealed that its joint venture Sunrise Guizhou's graphite anode material made from mid-sulfur petroleum coke offers a 3.2% higher specific capacity (357.8 mAh/g) compared to conventional low-sulfur coke (346.8 mAh/g). This improvement is due to increased internal porosity and fibrous structure from sulfur release during graphitization, enhancing battery performance and stability. The company has commercialized one product since 2023 and is preparing another for mass production, targeting large-format energy storage systems. This advancement supports better battery efficiency and durability, important for energy storage technology development.
E-Power's new graphite anode material with mid-sulfur coke is noted here for context. For readers following Basic Materials stocks, 19 of 83 US-listed shares on Pluang rose while 62 fell. Notable movers include AMRZ at USD 40.00 (+1.42%), IAUX at USD 1.47 (+1.38%), and CENX at USD 32.20 (-1.38%). This data is as of Oct 23, 2026 20:21 WIB.
The global computed tomography (CT) market is undergoing significant innovation driven by photon-counting technology, AI integration, mobile imaging, and point-of-care applications. These advancements are enhancing image quality, workflow efficiency,...
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...
